The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia.
Nineteen adult patients with type III hyperlipoproteinemia (HLP) and homozygosity for apolipoprotein (apo) E2 were treated with the 3-hydroxy-3-methyl glutaryl coenzyme A (HMG CoA) reductase inhibitor simvastatin (20 or 40 mg per day) alone or in combination with the fibrate derivative gemfibrozil (450 mg per day) during a 30-week outpatient study. With the 20-mg dose (n = 19) the mean plasma cholesterol level decreased from 13.24 +/- 8.04 at baseline to 8.04 +/- 4.19 mmol/l (mean reduction 39.3%; P < 0.05), and the mean plasma triglyceride level decreased from 13.47 +/- 19.22 to 7.84 +/- 7.71 mmol/l (-41.8%; NS); this was due to a decrease in very low density lipoprotein (VLDL) cholesterol from 8.95 +/- 8.64 to 4.94 +/- 4.24 mmol/l (-44.8%; NS), a decrease in low density lipoprotein (LDL) cholesterol from 3.54 +/- 0.93 to 2.25 +/- 0.59 mmol/l (-36.5%; P < 0.01), and an increase in high density lipoprotein (HDL) cholesterol from 0.72 +/- 0.28 to 0.85 +/- 0.34 (+18.1%; NS). Thirteen patients were treated with 40 mg simvastatin per day. Under this regimen there was a further significant decrease in LDL cholesterol from 2.33 +/- 0.62 to 1.81 +/- 0.49 mmol/l (-22.3%; P < 0.01). In six patients who remained hyperlipidemic on monotherapy combination drug therapy with simvastatin (40 mg per day) and gemfibrozil (450 mg per day) was given. Compared to simvastatin alone the addition of gemfibrozil further lowered plasma concentrations of total cholesterol by 14.9%, VLDL cholesterol by 23.5%, and triglycerides by 17.1%, although this was not statistically significant.(ABSTRACT TRUNCATED AT 250 WORDS)
Feussner
G
G
Abteilung Innere Medizin I, Universität Heidelberg.
Eichinger
M
M
Ziegler
R
R
D000328:Adult; D053329:Apolipoprotein E2; D001057:Apolipoproteins E / Q000235:genetics; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003131:Combined Modality Therapy; D004041:Dietary Fats / Q000008:administration & dosage; D004311:Double-Blind Method; D005260:Female; D015248:Gemfibrozil / Q000008:administration & dosage*; D006801:Humans; D006952:Hyperlipoproteinemia Type III / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D006951:Hyperlipoproteinemias / Q000178:diet therapy; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D008079:Lipoproteins, VLDL / Q000097:blood; D008148:Lovastatin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D019821:Simvastatin; D014280:Triglycerides / Q000097:blood
D053329:Apolipoprotein E2; D001057:Apolipoproteins E; D008078:Cholesterol, LDL; D004041:Dietary Fats; D008055:Lipids; D008074:Lipoproteins; D008079:Lipoproteins, VLDL; D014280:Triglycerides; D002784:Cholesterol; D008148:Lovastatin; D019821:Simvastatin; D015248:Gemfibrozil